Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CANCER SIGNALLING

Financiado

Cerrado

Identification and characterization of novel EGFR interactors and their implicat...

Identification and characterization of novel EGFR interactors and their implication in cancer signalling One of the major challenges of modern molecular biology is to understand how healthy cells transform into malignant, proliferating cells leading to diseases such as cancer and which proteins trigger these aberrant signalling casca... ver más

09/03/2016

UNIVERSITY COLLEGE...

222K€

Presupuesto del proyecto: 222K€

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-03-09 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIVERSITY COLLEGE LONDON

221.61K€ | Lider

UNIVERSITY COLLEGE LONDON

Proyectos interesantes

TRIPLECON

Medical Technol...

Data Science

150K€ Cerrado

MODSIGN

Medical Technol...

Data Science

100K€ Cerrado

ONCROBUST

Medical Technol...

Data Science

2M€ Cerrado

PID2019-106937RB-I00

Medical Technol...

Data Science

278K€ Cerrado

BFU2010-15923

Medical Technol...

Data Science

145K€ Cerrado

SAF2013-49056-R

Medical Technol...

Data Science

133K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 222K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto One of the major challenges of modern molecular biology is to understand how healthy cells transform into malignant, proliferating cells leading to diseases such as cancer and which proteins trigger these aberrant signalling cascades. The ErbB family of receptor tyrosine kinases (RTKs) are pivotal mediators of the signalling network that transmit extracellular signals into the cell and control cell growth, proliferation, differentiation and survival. Excessive ErbB signalling arises from receptor overexpression or mutation and is a hallmark of various cancers. Yet, despite 25 years of in-depth studies of RTK signalling, some aspects remain elusive and deeper understanding of signalling pathways downstream of mutant receptors will likely improve current EGFR-targeted therapies. Hence, the main aim of this proposal is to identify novel players in EGFR signalling as potential novel cancer drug targets. This will be achieved by transferring a novel two-hybrid technique that I have developed during my previous postdoc to the host institution and combining it with their expertise in cancer signalling. I will a) perform interaction screens to identify novel interactors of EGFR and its cancerous variants and b) perform small molecule compound screens to identify drugs that can interfere with interactions that specifically occur with these oncogenic EGFRs. Our ultimate goal is to identify chemical compounds that can be taken further to therapeutic development.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores